Medicines and Technology Programs, SA Health, Rundle Mall, Adelaide, SA 5000, Australia. Email:
Aust Health Rev. 2021 Mar;45(2):207-213. doi: 10.1071/AH20018.
Objective The South Australian Medicines Evaluation Panel (SAMEP) was established in 2011 to make evidence-based recommendations on the funding of high-cost medicines in South Australian public hospitals via a high-cost medicines formulary. SAMEP represents one component of South Australia's process for state-based health technology assessment (HTA). The aim of this study was to describe the experience of SAMEP in the context of Australia's complex governance model for hospital-based care. Methods A retrospective review was conducted of the SAMEP process and outcomes of medicine evaluations. Decision summaries and meeting minutes were reviewed and reflected upon by the authors to explore the views of the SAMEP membership regarding the function of the committee and state-based HTA more broadly. Results SAMEP has reviewed 29 applications, with 14 (48%) listed on the high-cost medicines formulary. Three applications have been the subject of outcome review and confirm expectations of patient benefit. Conclusion Retrospective review of the committee experience suggests that state-based HTA as operationalised by SAMEP is feasible, provides greater equity of access to high-cost medicines in the South Australian public hospital system and allows for access with evidence development. What is known about the topic? State-based hospital funders often need to make decisions on the provision of high-cost medicines for which there is no national guidance or subsidy. Little published information exists about state-based approaches to medicines evaluation and reimbursement within public hospitals in Australia. What does this paper add? The South Australian experience demonstrates a method for states and territories to tackle the challenges of providing evidence-based access to high-cost medicines in Australian public hospitals. What are the implications for practitioners? This paper provides information for other jurisdictions considering state-based approaches to medicines evaluation and contributes to the broader literature about state-based HTA in Australia.
目的
南澳大利亚药品评估小组（SAMEP）成立于 2011 年，通过高成本药品处方，对南澳大利亚公立医院的高成本药品进行循证推荐。SAMEP 是南澳大利亚州基于健康技术评估（HTA）的全州药品评估过程的一部分。本研究的目的是描述 SAMEP 在澳大利亚复杂的医院护理治理模式背景下的经验。
方法
对 SAMEP 程序和药品评估结果进行回顾性审查。决策摘要和会议记录由作者审查和反思，以探讨 SAMEP 成员对委员会职能和全州 HTA 的更广泛看法。
结果
SAMEP 已经审查了 29 项申请，其中 14 项（48%）列入了高成本药品处方。有 3 项申请已成为结果审查的主题，并确认了对患者受益的预期。
结论
对委员会经验的回顾性审查表明，SAMEP 实施的全州 HTA 是可行的，在南澳大利亚公立医院系统中为高成本药品提供了更大的公平性，并允许在证据开发的基础上获得准入。
关于该主题已知的情况是什么？
基于州的医院供资者通常需要就提供没有国家指导或补贴的高成本药品做出决定。关于澳大利亚公立医院药品评估和报销的基于州的方法，发表的信息很少。
这篇文章增加了什么？
南澳大利亚的经验展示了一种方法，各州和地区可以利用这种方法来应对在澳大利亚公立医院中提供基于证据的高成本药品准入的挑战。
这对从业者有什么影响？
本文为其他考虑基于州的药品评估方法的司法管辖区提供了信息，并为澳大利亚基于州的 HTA 的更广泛文献做出了贡献。
